GlobeNewswire Inc.··Greenwich Lifesciences, Inc.Greenwich LifeSciences Posts Promising FLAMINGO-01 Data on Breast Cancer Immunotherapy
Greenwich LifeSciences reports significant immune response gains in Phase III FLAMINGO-01 trial for GLSI-100 breast cancer recurrence prevention, showing 70-80% recurrence reduction.
GLSIbreast cancerGLSI-100